These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
    Journal: Am Rev Respir Dis; 1981 Feb; 123(2):165-70. PubMed ID: 7015933.
    Abstract:
    We compared the bacteriologic relapse between 5 and 28 months for five 4-month chemotherapeutic regimens for pulmonary tuberculosis. The regimens were: (1) streptomycin plus isoniazid plus rifampin plus pyrazinamide daily for 8 wk followed by isoniazid plus rifampin plus pyrazinamide daily for 9 wk; (2) the same 4 initial drugs for 8 wk followed by isoniazid plus rifampin daily for 9 wk; (3) the same 4 initial drugs for 8 wk followed by isoniazid plus pyrazinamide daily for 9 wk; (4) the same 4 drugs for 8 wk followed by isoniazid daily for 9 wk; (5) the same as regimen 4; but without streptomycin for the first 8 wk. The first 2 regimens, in which rifampin was given for 4 months, had relapse rates of 16 and 11%, respectively, but the rates were much higher for the regimens in which rifampin was given for only 2 months (32 and 30 %, respectively). The addition of pyrazinamide in the continuation phase had no effect on relapse rate. Removal of the streptomycin (regimen 5) resulted in a relapse rate of 40%, but this was not significantly higher than that (30%) after regimen 4 (p = 0.2).
    [Abstract] [Full Text] [Related] [New Search]